Fig. 2.

Percentage of non-progressors at (A) 6 months and (B) 1 year

LE and as-observed analyses. Non-progressor defined as a patient with a change from baseline in mTSS ≤0. In SELECT-COMPARE, at week 26 (6-month visit), patients receiving placebo were switched to upadacitinib. The month 6 analysis was conducted at week 24 in SELECT-EARLY and week 26 in SELECT-COMPARE; the year 1 analysis was conducted at week 48 in both studies. eow, every other week. ***P < 0.001 upadacitinib vs MTX or placebo; ^###P < 0.001 adalimumab vs placebo.